ofloxacin and fropenem

ofloxacin has been researched along with fropenem in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (25.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Brown, DG; Gagnon, MM; May-Dracka, TL; Tommasi, R	1
Hikida, M; Igarashi, A; Itahashi, K; Kitamura, M; Shiba, T	1
Fujimoto, N; Iihara, K; Inatomi, H; Kobayashi, T; Matsumoto, T; Muratani, T; Nishimura, T; Takahashi, K; Yamada, Y	1
Odagiri, S; Shimada, J; Takahashi, H; Watanuki, Y	1

Trials

1 trial(s) available for ofloxacin and fropenem

Article	Year
[Faropenem 300 mg 3 times daily versus levofloxacin 100 mg 3 times daily in the treatment of urinary tract infections in patients with neurogenic bladder and/or benign prostatic hypertrophy]. Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases, 2002, Volume: 76, Issue:11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; beta-Lactams; Drug Administration Schedule; Female; Humans; Lactams; Levofloxacin; Male; Middle Aged; Ofloxacin; Prostatic Hyperplasia; Urinary Bladder, Neurogenic; Urinary Tract Infections	2002

Article

Year

[Faropenem 300 mg 3 times daily versus levofloxacin 100 mg 3 times daily in the treatment of urinary tract infections in patients with neurogenic bladder and/or benign prostatic hypertrophy].

Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases, 2002, Volume: 76, Issue:11

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; beta-Lactams; Drug Administration Schedule; Female; Humans; Lactams; Levofloxacin; Male; Middle Aged; Ofloxacin; Prostatic Hyperplasia; Urinary Bladder, Neurogenic; Urinary Tract Infections

2002

Other Studies

3 other study(ies) available for ofloxacin and fropenem

Article	Year
Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens. Journal of medicinal chemistry, 2014, Dec-11, Volume: 57, Issue:23 Topics: Anti-Bacterial Agents; Blood Proteins; Drug Resistance, Multiple; Gram-Negative Bacteria; Gram-Positive Bacteria; High-Throughput Screening Assays; Humans; Hydrophobic and Hydrophilic Interactions; Microbial Sensitivity Tests; Protein Binding; Structure-Activity Relationship	2014
In vitro antibacterial activity of LJC 11,036, an active metabolite of L-084, a new oral carbapenem antibiotic with potent antipneumococcal activity. Antimicrobial agents and chemotherapy, 1999, Volume: 43, Issue:8 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Carrier Proteins; Cefdinir; Cephalosporins; Dipeptidases; Drug Stability; Escherichia coli Proteins; Hexosyltransferases; Imipenem; Lactams; Levofloxacin; Microbial Sensitivity Tests; Muramoylpentapeptide Carboxypeptidase; Ofloxacin; Penicillin-Binding Proteins; Peptidoglycan Glycosyltransferase; Peptidyl Transferases; Protein Binding; Serine-Type D-Ala-D-Ala Carboxypeptidase; Thienamycins	1999
[Epidemiological study on patients with pneumococcal respiratory tract infection in a Japanese health facility during the past year]. The Japanese journal of antibiotics, 2001, Volume: 54 Suppl B Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Cephalosporins; Chronic Disease; Clarithromycin; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Lactams; Male; Middle Aged; Ofloxacin; Pneumococcal Infections; Respiratory Tract Infections; Streptococcus pneumoniae; Time Factors	2001